Medical Condition

immunotherapy

Total Trials

11

Recruiting Now

11

Trial Phases

Phase 1, Phase 2, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for immunotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — immunotherapy Clinical Trials

How many clinical trials are currently recruiting for immunotherapy?

ClinicalMetric currently tracks 11 actively recruiting clinical trials for immunotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 11. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for immunotherapy?

immunotherapy research spans Phase 1 (2 trials), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a immunotherapy clinical trial?

Eligibility criteria for immunotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Anbogen Therapeutics, Inc. 1 trial

Sichuan University 1 trial

Universitair Ziekenhuis Brussel 1 trial

Mahidol University 1 trial

Qingdao Central Hospital 1 trial

Recruiting Clinical Trials

NCT07244705 Phase 1, Phase 2

Recruiting

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Anbogen Therapeutics, Inc.

View Trial →

NCT06603402 Phase 2

Recruiting

Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Survivors Treated With Immunotherapy and the Efficacy of Integrative Neurocognitive Remediation Therapy

Universitair Ziekenhuis Brusse...

View Trial →

NCT06035328

Recruiting

Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy

Nutrition Impact on Immunotherapy of Cancer

Qingdao Central Hospital

View Trial →

NCT06542796

Recruiting

Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma

Second Affiliated Hospital, Zh...

View Trial →

NCT07458529 Phase 2

Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Seventh Medical Center of PLA ...

View Trial →

NCT05266846 Phase 2

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Hunan Province Tumor Hospital

View Trial →

NCT06741982 Phase 1

Recruiting

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

The First Affiliated Hospital ...

View Trial →

NCT06429839 Phase 2

Recruiting

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Cancer Institute and Hospital,...

View Trial →

Related Conditions

neoadjuvant therapy (2) colorectal cancer diagnosis (1) colorectal cancer metastatic (1) colorectal cancer crc (1) esophageal squamous cell carcinoma escc (1) cognitive remediation (1) neuropsychology (1) quality of life (1) psycho oncology (1) cognitive behavioral therapy (1) cancer survivors (1) cognitive dysfunction (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology